Press Releases

Press Releases

IVI to Accelerate Efforts in iNTS Vaccine Development

IVI acquires GCLP certification from Korean Ministry of Food and Drug Safety

IVI Awarded $4.5 Million Grant to Increase Accessibility of Oral Cholera Vaccine

IVI Discusses Expanding Support for Global Collaboration on Vaccine R&D and Delivery with Top Foreign Diplomats in Seoul

IVI-led Consortium Awarded Fleming Fund Regional Grant to Improve Data Sharing in Fight against Antimicrobial Resistance

IVI to help developing countries tackle the spread of infectious diseases by building capacity through vaccinology training in Seoul

IVI acquires supplemental funding for Severe Typhoid in Africa Program (SETA Plus)

IVI Director General Dr. Jerome Kim to join the Human Vaccines Project’s Efforts as One of Four Distinguished Global Leaders to Decode the Human Immune System

Prof. Young Chul Sung, biotech leader, personally donates US$8.4 million to IVI

New push to develop world’s first vaccine against the deadly Strep A bacteria killing hundreds of thousand

IVI-led CAPTURA consortium wins Fleming Fund award for work on antimicrobial resistance (AMR) data across Asia

IVI receives $15.7 million grant to conduct phase III trials of new Vi-DT typhoid conjugate vaccine manufactured by SK bioscience of Korea

‘IVI Forum for Enhancement of Cooperation’ hosted jointly by the Korean Parliamentary Forum for Global Health, and KCDC under MOHW

Vaccine study confirms sensitivity of cholera test

Korean Pediatric Association, IVI, KSC exchange MOU

IVI receives $3.2 million grant to support TCV effectiveness studies in West Africa

CEPI partners with IVI to accelerate development of vaccines against emerging global health threats

Henry Lau joins IVI as Goodwill Ambassador

Nature Communications study addresses MDR typhoid

THSTI, IVI held joint symposium on Nov. 22

‘The Euvichol story’ published in Vaccine

IVI accelerates development of MERS vaccine

IVI’s 18th Vaccinology Course gathers 120 international participants from 19 countries in Seoul September 3-7

KOICA, IVI team up with Mozambican MoH and INS, partners to vaccinate 190,000 people against cholera

IVI acquires $5 million grant to support process development, scale up of typhoid conjugate vaccine with SK Bioscience

×

In Memoriam: Prof. Adel Mahmoud (1941 - 2018)

Author
tkbyun
Date
2018-06-14 05:17
Views
1373

The late Prof. Adel Mahmoud, former Chairman of the IVI Board of Trustees


The International Vaccine Institute (IVI) is greatly saddened by the June 11 passing of Prof. Adel Mahmoud, former Chairman of the IVI Board of Trustees and a global pioneer in the treatment and prevention of infectious diseases.


Prof. Mahmoud joined the IVI BOT as a member-at-large in 2010 and served as its Chairman from 2013 when IVI was going through a difficult period, before resigning due to health reasons in February of this year. He came to the IVI Board after a remarkable career in academia and industry, culminating as the President of Merck Vaccines.  Before passing away, he was a Professor of the Department of Molecular Biology and the Woodrow Wilson School of Public and International Affairs at Princeton University, USA.


IVI is a stronger and more vital institution because of Prof. Mahmoud’s vision and leadership. IVI is eternally grateful to him and would like to extend our deepest and most sincere condolences to his family and to all those who knew him, as we join the community in  the mourning of his loss. He will be remembered and dearly missed by IVI and the broader international community for his contributions to global health.


 

DONATE